Panagora Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.9M | Buy |
29,562
+19,219
| +186% | +$5.8M | 0.03% | 356 |
|
|
2026
Q1 | $3.42M | Sell |
10,343
-20,500
| -66% | -$6.98M | 0.01% | 482 |
|
|
2025
Q4 | $12.3M | Sell |
30,843
-31,511
| -51% | -$13.9M | 0.04% | 269 |
|
|
2025
Q3 | $28.4M | Sell |
62,354
-30,145
| -33% | -$12.3M | 0.11% | 169 |
|
|
2025
Q2 | $30.2M | Sell |
92,499
-4,305
| -4% | -$1.19M | 0.14% | 151 |
|
|
2025
Q1 | $26.1M | Buy |
96,804
+41,340
| +75% | +$10.6M | 0.13% | 155 |
|
|
2024
Q4 | $13.1M | Sell |
55,464
-70,427
| -56% | -$18.5M | 0.06% | 211 |
|
|
2024
Q3 | $34.6M | Buy |
125,891
+106,081
| +535% | +$27.6M | 0.17% | 125 |
|
|
2024
Q2 | $4.81M | Buy |
19,810
+12,353
| +166% | +$1.95M | 0.02% | 317 |
|
|
2024
Q1 | $1.11M | Hold |
7,457
| – | – | 0.01% | 760 |
|
|
2023
Q4 | $1.43M | Hold |
7,457
| – | – | 0.01% | 683 |
|
|
2023
Q3 | $1.32M | Buy |
7,457
+2,336
| +46% | +$446K | 0.01% | 686 |
|
|
2023
Q2 | $973K | Hold |
5,121
| – | – | 0.01% | 795 |
|
|
2023
Q1 | $1.03M | Sell |
5,121
-152
| -3% | -$31.9K | 0.01% | 826 |
|
|
2022
Q4 | $1.25M | Sell |
5,273
-1,079
| -17% | -$230K | 0.01% | 798 |
|
|
2022
Q3 | $1.27M | Sell |
6,352
-213
| -3% | -$40.6K | 0.01% | 762 |
|
|
2022
Q2 | $958K | Hold |
6,565
| – | – | 0.01% | 898 |
|
|
2022
Q1 | $1.07M | Buy |
6,565
+3,223
| +96% | +$491K | 0.01% | 905 |
|
|
2021
Q4 | $567K | Sell |
3,342
-2,667
| -44% | -$496K | ﹤0.01% | 1167 |
|
|
2021
Q3 | $1.14M | Hold |
6,009
| – | – | 0.01% | 910 |
|
|
2021
Q2 | $1.02M | Sell |
6,009
-411
| -6% | -$60.2K | 0.01% | 979 |
|
|
2021
Q1 | $906K | Buy |
6,420
+1,446
| +29% | +$218K | 0.01% | 1061 |
|
|
2020
Q4 | $646K | Buy |
4,974
+1,322
| +36% | +$177K | ﹤0.01% | 1134 |
|
|
2020
Q3 | $532K | Hold |
3,652
| – | – | ﹤0.01% | 1138 |
|
|
2020
Q2 | $541K | Buy |
3,652
+144
| +4% | +$19.4K | ﹤0.01% | 1174 |
|
|
2020
Q1 | $382K | Hold |
3,508
| – | – | ﹤0.01% | 1231 |
|
|
2019
Q4 | $404K | Buy |
3,508
+257
| +8% | +$25.6K | ﹤0.01% | 1373 |
|
|
2019
Q3 | $261K | Sell |
3,251
-699
| -18% | -$55.3K | ﹤0.01% | 1536 |
|
|
2019
Q2 | $287K | Hold |
3,950
| – | – | ﹤0.01% | 1650 |
|
|
2019
Q1 | $369K | Sell |
3,950
-728
| -16% | -$60.9K | ﹤0.01% | 1499 |
|
|
2018
Q4 | $341K | Buy |
4,678
+584
| +14% | +$44.9K | ﹤0.01% | 1453 |
|
|
2018
Q3 | $358K | Buy |
4,094
+979
| +31% | +$98.5K | ﹤0.01% | 1476 |
|
|
2018
Q2 | $307K | Buy |
3,115
+371
| +14% | +$36.8K | ﹤0.01% | 1515 |
|
|
2018
Q1 | $327K | Buy |
2,744
+19
| +0.7% | +$2.45K | ﹤0.01% | 1514 |
|
|
2017
Q4 | $346K | Hold |
2,725
| – | – | ﹤0.01% | 1483 |
|
|
2017
Q3 | $320K | Sell |
2,725
-1,607
| -37% | -$137K | ﹤0.01% | 1503 |
|
|
2017
Q2 | $346K | Buy |
4,332
+1,350
| +45% | +$86.3K | ﹤0.01% | 1471 |
|
|
2017
Q1 | $153K | Hold |
2,982
| – | – | ﹤0.01% | 1744 |
|
|
2016
Q4 | $112K | Hold |
2,982
| – | – | ﹤0.01% | 1912 |
|
|
2016
Q3 | $202K | Sell |
2,982
-953
| -24% | -$67.2K | ﹤0.01% | 1760 |
|
|
2016
Q2 | $218K | Sell |
3,935
-345
| -8% | -$21.7K | ﹤0.01% | 1638 |
|
|
2016
Q1 | $269K | Buy |
4,280
+972
| +29% | +$64.6K | ﹤0.01% | 1557 |
|
|
2015
Q4 | $311K | Sell |
3,308
-1,179
| -26% | -$109K | ﹤0.01% | 1465 |
|
|
2015
Q3 | $361K | Buy |
+4,487
| New | +$499K | ﹤0.01% | 1421 |
|
|
2014
Q3 | – | Sell |
-677
| Closed | -$43K | – | 2280 |
|
|
2014
Q2 | $43K | Hold |
677
| – | – | ﹤0.01% | 2123 |
|
|
2014
Q1 | $45K | Sell |
677
-232
| -26% | -$18K | ﹤0.01% | 2110 |
|
|
2013
Q4 | $58K | Hold |
909
| – | – | ﹤0.01% | 1951 |
|
|
2013
Q3 | $58K | Buy |
+909
| New | +$45.3K | ﹤0.01% | 1988 |
|
Other funds holding ALNY
Panagora Asset Management's ALNY Position: Q2 2026 in Review
Panagora Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 186% in Q2 2026, buying an estimated $5.8M and bringing the position to 29,562 shares worth $8.9M. The position accounts for 0.03% of the portfolio, ranked #356.
Panagora Asset Management first reported a position in ALNY in Q3 2013 and has held it in 48 quarters since. The position peaked at $34.6M in Q3 2024. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Panagora Asset Management held 29,562 shares of Alnylam Pharmaceuticals worth $8.9M as of Q2 2026.
- Panagora Asset Management bought 19,219 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.8M.
- Alnylam Pharmaceuticals made up 0.03% of Panagora Asset Management's portfolio in Q2 2026, its #356 holding.
- Panagora Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 48 quarters since.
- Panagora Asset Management's Alnylam Pharmaceuticals position peaked at $34.6M in Q3 2024.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.